E&C investigation
This article was originally published in The Tan Sheet
Executive Summary
The House Energy and Commerce Subcommittee on Oversight and Investigations announces Aug. 24 it is investigating FDA's plan to outsource jobs. Energy and Commerce Chairman John Dingell, D-Mich., and Subcommittee Chair Bart Stupak, D-Mich., say in a release they were "incredulous" when they learned of FDA's plan to outsource 332 positions. The news comes one week after Dingell and Stupak commended the Office of Regulatory Affairs' plan to shut down seven labs (1"The Tan Sheet" Aug. 27, 2007, p. 6). The congressmen are asking for a list of the positions as well as descriptions of job responsibilities, records reflecting the plans, budget analyses and more by Sept. 7...
You may also be interested in...
ORA Lab Closings Cancelled But Reorganization Not Off The Table – Staffers
FDA's head of regulatory affairs' Aug. 17 message to staff about cancelling plans to close seven field labs did not mark the end of the agency's ORA reorganization work, staff members say
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.